Newsbenzinga
Nurix Therapeutics Enrolls First Patient In Registrational Phase 3 DAYBreak CLL-306 Trial Of Bexobrutideg For Relapsed/Refractory CLL/SLL
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…